{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:03:13Z","timestamp":1789588993328,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jchromb.2025.124615","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:29:26Z","timestamp":1745940566000},"page":"124615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Simultaneous determination of Favipiravir and its active metabolite, Favipiravir Ribofuranosyl-5\u2032-triphosphate, in plasma and buccal cells using HPLC"],"prefix":"10.1016","volume":"1259","author":[{"given":"Yuriko","family":"Kondou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeka","family":"Obataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Uchikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Momo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124615_bb0005","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/2472555220942123","article-title":"RNA-dependent RNA polymerase as a target for COVID-19 drug discovery","volume":"25","author":"Zhu","year":"2020","journal-title":"SLAS Discovery."},{"key":"10.1016\/j.jchromb.2025.124615_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s15010-019-01364-9","article-title":"Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)","volume":"48","author":"Song","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.jchromb.2025.124615_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009103","article-title":"A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome","volume":"15","author":"Suemori","year":"2021","journal-title":"PLoS Neglected Trop Dis."},{"key":"10.1016\/j.jchromb.2025.124615_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103591","article-title":"Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome","volume":"72","author":"Yuan","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jchromb.2025.124615_bb0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-021-00541-3","article-title":"Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jchromb.2025.124615_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.antiviral.2018.06.013","article-title":"Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice","volume":"157","author":"Hawman","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jchromb.2025.124615_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105703","article-title":"Favipiravir and ribavirin protect immunocompetent mice from lethal CCHFV infection","volume":"218","author":"Tipih","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jchromb.2025.124615_bb0045","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s40121-021-00517-4","article-title":"Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial","volume":"10","author":"Shinkai","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.jchromb.2025.124615_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrmicro775","article-title":"SARS \u2013 beginning to understand a new virus","volume":"1","author":"Stadler","year":"2003","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jchromb.2025.124615_bb0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coviro.2014.01.010","article-title":"MERS: emergence of a novel human coronavirus","volume":"5","author":"Raj","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jchromb.2025.124615_bb0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s42398-021-00165-x","article-title":"Linkages between environmental issues and zoonotic diseases: with reference to COVID-19 pandemic","volume":"4","author":"Mishra","year":"2021","journal-title":"Environ. Sustain."},{"key":"10.1016\/j.jchromb.2025.124615_bb0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cpt.1878","article-title":"Response to \"dose rationale for favipiravir use in patients infected with SARS-CoV-2\"","volume":"108","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2025.124615_bb0080","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1111\/bcp.15227","article-title":"Pharmacokinetic characterization of favipiravir in patients with COVID-19","volume":"88","author":"G\u00fclhan","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2025.124615_bb0085","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/cts.12827","article-title":"Pharmacokinetics of favipiravir in critically ill patients with COVID-19","volume":"13","author":"Irie","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jchromb.2025.124615_bb0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijid.2021.12.324","article-title":"Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients","volume":"115","author":"Koseki","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.jchromb.2025.124615_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116155","article-title":"A novel LC-MS\/MS method for the determination of favipiravir ribofuranosyl-5\u2032-triphosphate (T-705-RTP) in human peripheral mononuclear cells","volume":"245","author":"Challenger","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2025.124615_bb0100","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3390\/molecules26133789","article-title":"Development and validation of a method for quantification of favipiravir as COVID-19 management in spiked human plasma","volume":"26","author":"Hailat","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jchromb.2025.124615_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5365","article-title":"A gadolinium-based magnetic ionic liquid for supramolecular dispersive liquid\u2013liquid microextraction followed by HPLC\/UV for the determination of favipiravir in human plasma","volume":"36","author":"Abdallah","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2025.124615_bb0110","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2116\/analsci.21N004","article-title":"Optimization of analytical procedure for in-hospital rapid quantification of serum level of favipiravir in the pharmacological treatment of COVID-19","volume":"37","author":"Moriiwa","year":"2021","journal-title":"Anal. Sci."},{"key":"10.1016\/j.jchromb.2025.124615_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115131","article-title":"Fabric phase sorptive extraction combined with high performance liquid chromatography for the determination of favipiravir in human plasma and breast milk","volume":"223","author":"Tiris","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2025.124615_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123547","article-title":"HPLC-DAD quantification of favipiravir in whole blood after extraction from volumetric absorptive microsampling devices","volume":"1215","author":"Azzahra Rahmadhani","year":"2023","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2025.124615_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2022.107580","article-title":"Rapid and ecofriendly UPLC quantification of remdesivir, favipiravir and dexamethasone for accurate therapeutic drug monitoring in Covid-19 patient's plasma","volume":"179","author":"Emam","year":"2022","journal-title":"Microchem. J."},{"key":"10.1016\/j.jchromb.2025.124615_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2023.115375","article-title":"Simultaneous determination of favipiravir and surrogates of its metabolites by means of heart-cutting bidimensional liquid chromatography (2D-LC)","volume":"684","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2024","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2025.124615_bb0135","article-title":"A novel, rapid and simple UPLC\u2013MS\/MS method for quantification of favipiravir in human plasma: application to a bioequivalence study","volume":"35","author":"Rezk","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2025.124615_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.22159\/ajpcr.2021.v14i7.41966","article-title":"Ultraviolet spectrophotometric method development for estimation of new antiviral repurposing drug favipiravir","volume":"14","author":"Jyothi","year":"2021","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"10.1016\/j.jchromb.2025.124615_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2020.119241","article-title":"Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: application to spiked human plasma","volume":"249","author":"Megahed","year":"2021","journal-title":"Spectrochim. Acta A"},{"key":"10.1016\/j.jchromb.2025.124615_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2021.338418","article-title":"First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: a study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode","volume":"1159","author":"Allahverdiyeva","year":"2021","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jchromb.2025.124615_bb0155","article-title":"Innovative electrochemical sensor for the precise determination of the new antiviral COVID-19 treatment favipiravir in the presence of coadministered drugs","volume":"895","author":"Mona","year":"2021","journal-title":"J. Electroanal. Chem."},{"key":"10.1016\/j.jchromb.2025.124615_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jchromb.2025.124615_bb0165","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/cea.13746","article-title":"Expression of ACE2 in airways: implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases","volume":"50","author":"Yao","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.jchromb.2025.124615_bb0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/08830185.2021.1967949","article-title":"COVID-19 and oral diseases: assessing manifestations of a new pathogen in oral infections","volume":"41","author":"Naqvi","year":"2021","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.jchromb.2025.124615_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2248","article-title":"Oral manifestations of Covid-19-a literature review","volume":"32","author":"Farid","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.jchromb.2025.124615_bb0180","doi-asserted-by":"crossref","first-page":"395","DOI":"10.14639\/0392-100X-N1584","article-title":"COVID-19 manifestation in the oral cavity - a narrative literature review","volume":"41","author":"Kusiak","year":"2021","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"10.1016\/j.jchromb.2025.124615_bb0185","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/JPER.21-0277","article-title":"The \"oral\" history of COVID-19: primary infection, salivary transmission, and post-acute implications","volume":"92","author":"Marchesan","year":"2021","journal-title":"J. Periodontol."},{"key":"10.1016\/j.jchromb.2025.124615_bb0190","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJM197208312870903","article-title":"Salicylate accumulation kinetics in man","volume":"287","author":"Levy","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2025.124615_bb0195","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/ac020064n","article-title":"Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry","volume":"74","author":"Soga","year":"2002","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2025.124615_bb0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0378-4347(93)E0381-Y","article-title":"Direct gradient reversed-phase high-performance liquid chromatographic determination of salicylic acid, with the corresponding glycine and glucuronide conjugates in human plasma and urine","volume":"652","author":"Vree","year":"1994","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2025.124615_bb0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0378-4347(95)00337-1","article-title":"Direct analysis of salicylic acid, salicyl acyl glucuronide, salicyluric acid and gentisic acid in human plasma and urine by high-performance liquid chromatography","volume":"675","author":"Liu","year":"1996","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2025.124615_bb0215","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkab135","article-title":"Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5\u2032-triphosphate exposure to support posology for SARS-CoV-2","volume":"76","author":"Pertinez","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2025.124615_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113935","article-title":"Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC\u2013MS\/MS method in human serum","volume":"196","author":"Habler","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2025.124615_bb0225","article-title":"Development and validation of a sensitive, fast and simple LC-MS \/ MS method for the quantitation of favipiravir in human serum","volume":"1176","author":"Onmaz","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2025.124615_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115436","article-title":"Development and validation of an LC-MS\/MS method for quantification of favipiravir in human plasma","volume":"233","author":"Challenger","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2025.124615_bb0235","article-title":"Green profile tools: current status and future perspectives","volume":"6","author":"Locatelli","year":"2023","journal-title":"Adv Sample Prep."},{"key":"10.1016\/j.jchromb.2025.124615_bb0240","article-title":"Click analytical chemistry index as a novel concept and framework, supported with open source software to assess analytical methods","volume":"14","author":"Mansour","year":"2025","journal-title":"Adv Sample Prep."},{"key":"10.1016\/j.jchromb.2025.124615_bb0245","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/analytica5030030","article-title":"Modified GAPI (MoGAPI) tool and software for the assessment of method greenness; case studies and applications","volume":"5","author":"Mansour","year":"2024","journal-title":"Analytica"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T13:12:36Z","timestamp":1746882756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":45,"alternative-id":["S1570023225001692"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124615","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of Favipiravir and its active metabolite, Favipiravir Ribofuranosyl-5\u2032-triphosphate, in plasma and buccal cells using HPLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124615"}}